Article

3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 54, n° 6
pages 1083-1088 (juin 2006)
Doi : 10.1016/j.jaad.2006.01.011
BRIEF REPORTS

Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation
 

Whitney A. High, MD a, , Amit G. Pandya, MD b
a From the University of Colorado Health Sciences Center 
b University of Texas Southwestern Medical Center. Completed as part of Dr High’s residency requirements at the University of Texas Southwestern Medical Center 

Reprint requests: Whitney A. High, MD, University Dermatopathology Associates, University of Colorado Health Sciences Center, PO Box 6510, Mail Stop F703, Denver, CO 80045-0510.

Denver, Colorado, and Dallas, Texas

Abstract
Background

African Americans with seborrheic dermatitis may manifest associated hypopigmenation. Corticosteroids and antifungals are often used for treatment, yet chronic use of corticosteroids may be associated with skin atrophy, increased intraocular pressure, or further hypopigmenation. Pimecrolimus has been used successfully in a few patients with seborrheic dermatitis.

Objectives

This open-label, pilot trial assessed the efficacy and tolerability of pimecrolimus in the treatment of seborrheic dermatitis in African Americans with hypopigmentation.

Methods

Five African American adults with seborrheic dermatitis used a thin layer of pimecrolimus on the involved areas twice per day for 16 weeks. Clinical measures of improvement included erythema, scaling, and pruritus. Hypopigmentation was measured objectively using a mexameter.

Results

All participants noted a marked decrease in the severity of their condition. An improvement in hypopigmentation was also noted. For all indicators, the magnitude of improvement was most marked during the initial 2 weeks of treatment.

Limitations

This was an open-label pilot trial limited to just 6 participants, only 5 of whom completed the study.

Conclusions

Topical pimecrolimus cream may be an excellent alternative therapeutic modality for treating seborrheic dermatitis in African Americans, particularly in those with associated hypopigmentation.

The full text of this article is available in PDF format.

 Supported by departmental resources at University of Texas Southwestern (UTSW) for resident-derived research projects. During the same fiscal year, the UTSW Department of Dermatology did receive a $2500.00 unrestricted educational grant from Novartis Pharmaceuticals Inc.
Disclosure: Dr Pandya is on the speaker bureau for Novartis Pharmaceuticals Inc.



© 2006  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline